Combining European cohort data to find biomarkers that guide treatment for venous thromboembolism
CoMbination of Data From European Cohorts as Part of the European MORPHEUS Project [HORIZON-HLTH-2022-11-01] - "MC-MORPHEUS".
University Hospital, Brest · NCT07328152
This project combines clinical, biological and imaging data from European patient cohorts to try to find biomarkers that predict clot recurrence, bleeding, or death in people with venous thromboembolism.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20000 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Brest (other) |
| Locations | 1 site (Brest) |
| Trial ID | NCT07328152 on ClinicalTrials.gov |
What this trial studies
The MORPHEUS programme brings together clinical, biological, morphological and socio-anthropological data from 14 French and European cohorts into one harmonized database. Using systematic literature review, cohort fusion and both quantitative and qualitative methods, the project will search for biomarkers that discriminate risk of thromboembolic recurrence, bleeding and mortality after venous thromboembolism. MC-MORPHEUS is the data-aggregation phase focused on identifying those predictive markers that will feed a time-dependent, multi-level prediction tool. That tool is intended to be integrated into shared medical decision-making and later validated in a randomized stepped-wedge cluster trial.
Who should consider this trial
Good fit: Ideal candidates are people with unprovoked venous thromboembolism who are participants in one of the cohorts led by members of the European MORPHEUS consortium and who have given consent for data use.
Not a fit: Patients who are not enrolled in the participating cohorts, who have not given consent for data sharing, or whose VTE was provoked by a clear transient cause are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could help personalize how long and which anticoagulant treatments patients receive, potentially reducing repeat clots and bleeding.
How similar studies have performed: Previous research has produced risk scores and candidate biomarkers for VTE outcomes, but large multicountry efforts combining clinical, biological, imaging and socio-anthropological data like MORPHEUS are novel and not yet validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cohorts led by members of the European MORPHEUS project consortium European MORPHEUS project Exclusion Criteria: * Lack of consent in cohorts
Where this trial is running
Brest
- Chu Brest — Brest, France (RECRUITING)
Study contacts
- Study coordinator: Francis COUTURAUD
- Email: francis.couturaud@chu-brest.fr
- Phone: 298347348
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Venous Thromboembolism, pulmonary embolism, Anticoagulant, deep vein thrombosis